Press releases
- Sarepta Therapeutics to Announce First Quarter 2024 Financial Results
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sarepta Therapeutics to Present at Upcoming Investor Conferences
- Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
- Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
- Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
- Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
- Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
More ▼
Key statistics
As of last trade Sarepta Therapeutics Inc (AB3A:FRA) traded at 118.60, -18.54% below its 52-week high of 145.60, set on May 16, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 118.60 |
---|---|
High | 118.60 |
Low | 118.60 |
Bid | 121.90 |
Offer | 122.45 |
Previous close | 115.10 |
Average volume | 2.22 |
---|---|
Shares outstanding | 93.86m |
Free float | 88.72m |
P/E (TTM) | -- |
Market cap | 11.96bn USD |
EPS (TTM) | -6.15 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 07:01 BST.
More ▼